peculiar https://t.co/B34i2fvOURAnsem (@blknoiz06):crypto app makes $630M in total revenue in < 1 year, & is raising another $1.3B in latest token saleso they'll have ~$2B in cash to scale & most of CT is routing for their downfall, peculiar ...

Product Focus - The company aims to create a smartphone that reduces excessive screen time and promotes focus [1] - The product differentiates itself in the market with a unique design that appeals to tech enthusiasts [2] Financial Performance - The company projects approximately $1 billion (USD) in revenue this year [3] - The company's revenue more than doubled from over $500 million (USD) last year [3] Target Audience - The company is targeting young creatives as its primary consumer base [3]

RT João Mendonça (@joaomendoncaaaa)@blknoiz06 they thought TVL was more important than revenue ...

Blackrock is printing on BTC ETF revenue https://t.co/E471cmYvYe ...

MARKET: 📊 Year over year, stablecoin issuers have generated nearly $10B in revenue.Tether leads with $6.56B, Circle earns $1.89B, Sky Protocol $384M and Ethena $332M.(Source: @CoinDeskData) https://t.co/bBS8bm06g7 ...

BlackRock's Bitcoin ETF earns more revenue than its $624 billion S&P 500 fund: Bloomberg https://t.co/Ilnm4MNWnp ...

RT DMH 🦇🔊🌊 (@DeFi_Made_Here)I think @hosseeb is somewhat rightPeople started speaking about revenues only after 2 projects in the whole defi (both extremely centralized) started earning substantial revenue (and it didn’t happen overnight!)Other than that we have so many examples like uniswap which is valued at $7b, spending hundreds of millions in incentives, and earned $0 in 7 years, or morpho which is pending $100m+ publicly and god knows how much privately to stimulate growth also with 0 revenue and uncl ...

How do you feel. Chris. We could see a 66% pop in the shares.Wow. I feel great. Today is such a momentous day for all of us here at Chime.We're so grateful to our members who rely on us for their everyday banking. And I'm just incredibly grateful for this team around me that has built a business that we really see as ushering in a new era for banking and one that's aligned with the best interests of everyday members. Chris We made a lot in the show over the years of kind of the down rounds, the valuation of ...

Core Viewpoint - APA Corporation reported a decline in adjusted earnings for Q4 2024, primarily due to lower commodity prices and increased costs, despite a significant rise in revenues driven by acquisitions and production increases [1][2]. Financial Performance - Adjusted earnings per share for Q4 2024 were 79 cents, missing the Zacks Consensus Estimate of 97 cents and down from $1.15 in the previous year [1]. - Revenues reached $2.5 billion, a 32% increase from the same quarter last year, and exceeded the Zacks Consensus Estimate by 10% [2]. - The company generated $1 billion in cash from operating activities and reported a free cash flow of $420 million, up from $292 million a year ago [7]. Production & Selling Prices - Average production of oil and natural gas was 488,308 BOE/d, a 17.8% increase year-over-year, surpassing expectations [3]. - U.S. output increased by 37% year-over-year to 313,227 BOE/d, while international production decreased by 5.7% to 175,081 BOE/d [4]. - The average realized crude oil price was $72.42 per barrel, down 11% from $81.36 a year ago, but above the projected $68 [5]. Costs & Financial Position - Lease operating expenses totaled $474 million, a 31.7% increase from $360 million in the previous year [6]. - Total operating expenses surged 48.1% year-over-year to $2 billion, significantly higher than the model estimate of $2.9 billion [6]. - As of December 31, APA had approximately $625 million in cash and cash equivalents and $6 billion in long-term debt, resulting in a debt-to-capitalization ratio of 53.2% [8]. Guidance - APA expects adjusted production to average 399,000 BOE/d in Q1 2025 and 396,000 BOE/d for the full year, representing a 3% year-over-year increase [9]. - The company has set its upstream capital expenditure for the year at $2.5-$2.6 billion [9].

Core Insights - BeiGene, Ltd. reported a revenue of $1.13 billion for the quarter ended December 2024, marking a 77.8% increase year-over-year and exceeding the Zacks Consensus Estimate of $1.09 billion by 3.76% [1] - The company's EPS was -$1.43, an improvement from -$3.53 in the same quarter last year, but fell short of the consensus estimate of -$0.88, resulting in a surprise of -62.50% [1] Revenue Breakdown - Product revenue reached $1.12 billion, surpassing the average estimate of $1.08 billion by analysts, reflecting a 77.3% increase compared to the previous year [4] - BRUKINSA (Zanubrutinib) generated $828.03 million, exceeding the average estimate of $764.99 million [4] - Tislelizumab revenue was $153.80 million, below the average estimate of $174.58 million [4] - REVLIMID revenue was $3.56 million, significantly lower than the estimated $10.17 million [4] - Other product revenues included $18.24 million for Other, $62.52 million for XGEVA, $13.11 million for POBEVCY, $20.62 million for BLINCYTO, and $18.15 million for KYPROLIS, with most figures falling short of analyst estimates [4] - Collaboration revenue was reported at $9.79 million, exceeding the average estimate of $6.22 million, representing a 152.1% increase year-over-year [4] Stock Performance - Over the past month, BeiGene's shares have returned +14.2%, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]